ICMR Invites Expressions of Interest for Monkeypox Detection Technology

Collaborating organizations will engage in technology transfer with ICMR, enabling them to develop, manufacture, sell, and market the monkeypox detection assay.

The Indian Council of Medical Research (ICMR) has announced an invitation for organizations, companies, and manufacturers to submit Expressions of Interest (EoI) for the commercialization of a colorimetric isothermal (LAMP) assay designed for the rapid detection of the monkeypox virus.

This innovative tool, developed by the ICMR’s National Institute of Virology (NIV), aims to enhance public health response capabilities in managing and containing monkeypox outbreaks.

As one of the oldest medical research organizations in the world, ICMR has a long-standing commitment to advancing biomedical research while providing practical health solutions.

The ICMR-National Institute of Virology has played a critical role in addressing public health challenges, particularly during the Covid-19 pandemic.

By leveraging its expertise, the institute has developed a rapid colorimetric isothermal assay for monkeypox detection, which is poised to make a significant impact on public health by enabling early detection and effective management of outbreaks.

Key Details of the EoI Process

The ICMR’s EoI document, which outlines the necessary qualifications, submission requirements, and evaluation criteria, can be accessed on the ICMR website at [icmr.gov.in](https://www.icmr.gov.in).

Interested parties are encouraged to submit their proposals by November 9, 2024, in a sealed envelope addressed to the ICMR headquarters in New Delhi.

Submissions must indicate “EoI for Transfer of Technology for commercialization of a colorimetric isothermal (LAMP) assay for rapid detection of monkeypox virus.”

Opportunities for Eligible Companies

The ICMR is seeking to license this innovative monkeypox detection assay technology, granting manufacturing rights to eligible organizations for further development, production, and commercialization.

Selected companies will be empowered to conduct additional research and development, facilitating the introduction of this vital diagnostic tool to the market and improving accessibility for healthcare providers.

Collaborating organizations will engage in technology transfer with ICMR, enabling them to develop, manufacture, sell, and market the monkeypox detection assay.

Licensing agreements will be structured to promote either joint development or exclusive/non-exclusive arrangements, ensuring broad distribution of the technology.

Throughout the production process, ICMR-National Institute of Virology will provide technical guidance to ensure the quality and efficacy of the developed products.

The commercialization of the monkeypox detection assay will adhere to ICMR’s Intellectual Property Policy, approved by the Competent Authority, ensuring compliance with regulatory standards and effective management of intellectual property rights.

This colorimetric LAMP assay for monkeypox detection represents a significant advancement in viral diagnostics and aligns with ICMR’s mission to offer practical, scalable health solutions.

By inviting eligible organizations to participate in the technology transfer process, ICMR aims to facilitate the widespread availability of this essential diagnostic tool, thereby enhancing rapid response capabilities and contributing to the containment of monkeypox outbreaks.

ICMR retains the right to amend or cancel the EoI process at any time and may update additional information on its website as necessary.

Stay tuned for more such updates on Digital Health News.